Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOTRICITY INC.BTCY · Entity 8507 | Director · President, CEO and Chairman | March 12, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOTRICITY INC.
Report date March 12, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2033-01-27 | Direct | 3,549,984 |
Reported balance
After 2023-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-12 · Grant · Acquired 350,000 · Balance 3,549,984 F1: Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024. |
| Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2033-01-27 | Direct | 3,899,984 |
Reported balance
After 2023-03-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-12 · Grant · Acquired 350,000 · Balance 3,899,984 F1: Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024. |
| Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2033-01-27 | Direct | 4,899,984 |
Reported balance
After 2023-03-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-12 · Grant · Acquired 1,000,000 · Balance 4,899,984 F2: Granted pursuant to the 2016 Equity Incentive Plan, with 250,000 of the Option vested January 27, 2023, and the remaining unvested Option of 20,833 will become vested and exercisable every month thereafter starting on February 27, 2023, until the Option is 100% vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024.
F2: Granted pursuant to the 2016 Equity Incentive Plan, with 250,000 of the Option vested January 27, 2023, and the remaining unvested Option of 20,833 will become vested and exercisable every month thereafter starting on February 27, 2023, until the Option is 100% vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2023 Filed Mar 14, 2023 16:26 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 1,000,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001493152-23-007604 · ownership.xml · derivative · entry 3 Al-Siddiq Waqaas · CIK 0001783199 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,899,984 Underlying: Common Stock · 1,000,000 shares Expires 2033-01-27 F2 · derivative.exercise_date: Granted pursuant to the 2016 Equity Incentive Plan, with 250,000 of the Option vested January 27, 2023, and the remaining unvested Option of 20,833 will become vested and exercisable every month thereafter starting on February 27, 2023, until the Option is 100% vested. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 16:26 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 350,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001493152-23-007604 · ownership.xml · derivative · entry 2 Al-Siddiq Waqaas · CIK 0001783199 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,899,984 Underlying: Common Stock · 350,000 shares Expires 2033-01-27 F1 · derivative.exercise_date: Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 16:26 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 350,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-23-007604 · ownership.xml · derivative · entry 1 Al-Siddiq Waqaas · CIK 0001783199 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,549,984 Underlying: Common Stock · 350,000 shares Expires 2033-01-27 F1 · derivative.exercise_date: Granted pursuant to the 2016 Equity Incentive Plan, with 175,000 of the Option vested January 27, 2023, and the remaining unvested Option of 175,000 will vest on January 27, 2024. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 17:08 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 1,400,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-20-006129 · ownership.xml · derivative · entry 1 Al-Siddiq Waqaas · CIK 0001783199 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2030-04-07 F1 · derivative.exercise_date: The options vest quarterly over four years. Read SEC document |
| April 07, 2020 Filed Jun 3, 2020 16:34 UTC Amendment | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 1,400,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-20-010471 · ownership.xml · derivative · entry 1 Al-Siddiq Waqaas · CIK 0001783199 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2025-04-07 F1 · derivative.exercise_date: The options vest quarterly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.